Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.41+0.05 (+13.12%)
Close on Nov 18, 2026Market cap $99.30MP/E –Yield –
Outlook Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Outlook Therapeutics's enterprise value was $78.75M on Nov 11, 2026, against $88.38M a year earlier. Over the last 5 years it ranged from $4.61M to $402.97M, with a median of $103.32M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $78.75M | +2.2% |
| 2025 | Dec 31, 2025 | $77.06M | +154.7% |
| 2024 | Dec 31, 2024 | $30.25M | -61.8% |
| 2023 | Dec 29, 2023 | $79.15M | -65.3% |
| 2022 | Dec 30, 2022 | $228.10M | +1.1% |
| 2021 | Dec 31, 2021 | $225.51M | +47.6% |
| 2020 | Dec 31, 2020 | $152.80M | -85.9% |
| 2019 | Dec 31, 2019 | $1.09B | +3040.6% |
| 2018 | Dec 31, 2018 | $34.56M | +17.4% |
| 2017 | Dec 29, 2017 | $29.43M | -57.4% |
| 2016 | Dec 30, 2016 | $69.10M | – |
See a number that looks wrong?